Shares of Nektar Therapeutics (NASDAQ:NKTR) traded today at $11.34, breaking its 52-week high. So far today approximately 878,000 shares have been exchanged, as compared to an average 30-day volume of 834,000 shares.
Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.
Nektar Therapeutics share prices have moved between a 52-week high of $11.34 and a 52-week low of $5.65 and are now trading 96% above that low price at $11.06 per share. Over the past week, the 200-day moving average (MA) has gone up 0.6% while the 50-day MA has advanced 1.6%.
There is potential upside of 8.5% for shares of Nektar Therapeutics based on a current price of $11.06 and an average consensus analyst price target of $12.00. The stock should discover initial support at its 50-day moving average (MA) of $10.03 and subsequent support at its 200-day MA of $8.87.